(SFZN) Siegfried Holding - Ratings and Ratios

Siegfried Holding AG is a leading global contract development and manufacturing organization (CDMO) for active pharmaceutical ingredients (APIs) and finished dosage forms, serving the pharmaceutical industry worldwide. With a rich history dating back to 1873, the company has established itself as a trusted partner, leveraging its expertise in chemical synthesis, formulation, and manufacturing to deliver high-quality products and services.

The companys comprehensive portfolio encompasses a broad range of services, including exclusive synthesis, API manufacturing, and finished dosage forms, such as steriles, ophthalmics, inhalation products, and oral solid dosage forms. Additionally, Siegfried offers advanced technologies, including chemistry capabilities, analytical services, formulation technologies, and cell and gene therapies, making it a one-stop-shop for pharmaceutical companies.

With a strong presence in the global pharmaceutical industry, Siegfried has built a reputation for delivering high-quality products and services, with a focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases. The companys expertise in gene therapy, including viral vectors such as AAV and lentiviruses, positions it for growth in this rapidly evolving field.

Analyzing the companys technical data, we observe a current price of 97.10 CHF, with a 20-day SMA of 95.96 CHF and a 50-day SMA of 92.77 CHF, indicating a positive short-term trend. The 200-day SMA at 102.30 CHF suggests a longer-term downtrend. Considering the fundamental data, Siegfrieds market capitalization stands at 4228.02M CHF, with a P/E ratio of 26.18 and a forward P/E of 25.64, indicating a relatively stable valuation. The companys RoE of 32.00% demonstrates strong profitability.

Based on the technical and fundamental data, our forecast suggests that Siegfried Holding AG is poised for a potential rebound, driven by its strong industry position, comprehensive portfolio, and solid financials. With the 52-week high and low at 117.69 CHF and 80.15 CHF, respectively, and an ATR of 31.19 CHF (32.12%), we anticipate a potential price target of 110 CHF in the medium term, driven by the companys growth prospects in the pharmaceutical industry, particularly in gene therapy and other emerging areas.